Ken Griffin Replimune Group, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Replimune Group, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,700 shares of REPL stock, worth $50,925. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,700

Previous 8,000 21.25%

Holding current value

$50,925

Previous $96,000 2.08%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$9.75 - $14.31 $1.11 Million - $1.63 Million	-113,609 Reduced 83.31%	22,755 $221,000
Q4 2024 Feb 14, 2025	BUY	$10.54 - $14.93 $6,165 - $8,734	585 Added 0.43%	136,364 $1.65 Million
Q3 2024 Nov 14, 2024	SELL	$8.09 - $11.23 $639,975 - $888,371	-79,107 Reduced 36.81%	135,779 $1.49 Million
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $738,704 - $1.39 Million	147,446 Added 218.63%	214,886 $1.93 Million
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $962,466 - $1.3 Million	-140,097 Reduced 67.5%	67,440 $550,000
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $6.68 Million - $16 Million	-989,498 Reduced 82.66%	207,537 $1.75 Million
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $972,235 - $1.35 Million	60,917 Added 5.36%	1,197,035 $20.5 Million
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $331,873 - $511,064	21,206 Added 1.9%	1,136,118 $26.4 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $9.77 Million - $16.3 Million	558,936 Added 100.53%	1,114,912 $19.7 Million
Q4 2022 Feb 14, 2023	SELL	$17.09 - $27.91 $1.54 Million - $2.51 Million	-90,047 Reduced 13.94%	555,976 $15.1 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $978,213 - $1.33 Million	62,706 Added 10.75%	646,023 $11.2 Million
Q2 2022 Aug 15, 2022	BUY	$13.32 - $19.98 $3.27 Million - $4.9 Million	245,262 Added 72.55%	583,317 $10.2 Million
Q1 2022 May 16, 2022	SELL	$15.24 - $29.75 $2 Million - $3.91 Million	-131,530 Reduced 28.01%	338,055 $5.74 Million
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $2.27 Million - $3.06 Million	89,350 Added 23.5%	469,585 $12.7 Million
Q3 2021 Nov 15, 2021	SELL	$28.98 - $39.54 $325,764 - $444,469	-11,241 Reduced 2.87%	380,235 $11.3 Million
Q2 2021 Aug 16, 2021	SELL	$28.5 - $39.37 $9.77 Million - $13.5 Million	-342,821 Reduced 46.69%	391,476 $15 Million
Q1 2021 May 17, 2021	SELL	$30.22 - $45.57 $13 Million - $19.6 Million	-430,202 Reduced 36.94%	734,297 $22.4 Million
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $16.8 Million - $37.6 Million	714,087 Added 158.54%	1,164,499 $44.4 Million
Q3 2020 Nov 16, 2020	SELL	$18.85 - $27.0 $43,336 - $62,073	-2,299 Reduced 0.51%	450,412 $10.4 Million
Q2 2020 Aug 14, 2020	SELL	$9.76 - $25.95 $382,269 - $1.02 Million	-39,167 Reduced 7.96%	452,711 $11.3 Million
Q1 2020 May 15, 2020	SELL	$8.9 - $19.08 $316,163 - $677,797	-35,524 Reduced 6.74%	491,878 $4.9 Million
Q4 2019 Feb 14, 2020	BUY	$11.61 - $17.21 $3.86 Million - $5.72 Million	332,486 Added 170.58%	527,402 $7.57 Million
Q3 2019 Nov 14, 2019	BUY	$10.01 - $16.87 $86,436 - $145,672	8,635 Added 4.64%	194,916 $2.71 Million
Q2 2019 Aug 14, 2019	BUY	$12.51 - $17.28 $125,212 - $172,955	10,009 Added 5.68%	186,281 $2.73 Million
Q1 2019 May 15, 2019	SELL	$10.26 - $16.24 $579,515 - $917,283	-56,483 Reduced 24.27%	176,272 $0
Q4 2018 Feb 14, 2019	SELL	$9.97 - $15.57 $1.56 Million - $2.44 Million	-156,780 Reduced 40.25%	232,755 $2.33 Million
Q3 2018 Nov 13, 2018	BUY	$14.99 - $22.14 $5.84 Million - $8.62 Million	389,535 New	389,535 $0

Others Institutions Holding REPL

# of Institutions

176

Shares Held

78M

Call Options Held

219K

Put Options Held

216K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $259M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account